Clinical Trials
20 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT07318805 2026-05-08
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Recruiting
NCT06835569 2026-05-06
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1 Recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05040568 2026-01-26
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT01254617 2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1 Completed
NCT01287130 2019-12-17
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00497497 2017-05-19
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Genentech, Inc.
Phase 1 Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01294826 2015-06-08
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Swedish Medical Center
Phase 1 Completed
NCT01198535 2015-05-18
Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01217450 2014-05-29
Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00134069 2014-04-16
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01637194 2012-07-11
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT01126450 2012-03-20
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00494611 2011-05-19
A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients
St. Luke's-Roosevelt Hospital Center
Phase 1 Terminated